11 results about "Membrane bound protein" patented technology

Provided herein are novel compounds of Formula I, pharmaceutical compositions, and methods of using related to membrane bound protein, such as GPR40. The compounds herein are typically GPR40 agonists, which can be used for treating a variety of disorders, conditions or diseases such as Type 2 diabetes.

To provide assays for the detection and / or quantification of membrane-associated proteins, e.g., circulating CD20 (cCD20), incorporating an extracellular vesicle-based calibrator comprising the membrane-associated tumor antigen as well as the use of such assays in the detection and treatment of hyperproliferative disorders.SOLUTION: An assay for detecting a membrane-associated protein in a sample, comprises: a) a capture antibody that binds to an extracellular vesicle comprising the membrane-associated protein in the sample, thereby generating a capture antibody-extracellular vesicle complex; and b) a detection antibody that binds to the capture antibody-extracellular vesicle complex to form a detectable bound complex, where a signal from the detectable bound complex is calibrated against one or more known values detected from the extracellular vesicle comprising the protein.SELECTED DRAWING: Figure 1

The present invention relates to the field of binding molecules. In particular, the present invention relates to the field of therapeutic binding molecules for the treatment of diseases involving abnormal cells, such as cancer cells. In particular, the present invention relates to multispecific antibodies that bind to the extracellular portion of two or more different membrane-associated proteins, thereby modulating the biological activity expressed by the cells, and the use of such antibodies in combination therapy.

Immune cells engineered to express a chimeric antigen receptor (CAR) along with a TGF-beta dominant negative receptor (TGFβ DNR) and / or a membrane-bound IL15 protein (mbIL 15) are provided which are suitable for the treatment of diseases such as cancer.

Provided are novel fusion proteins, nucleic acids encoding said proteins, vectors comprising said nucleic acids, compositions comprising said nucleic acids or vectors, host cells comprising said nucleic acids, vectors or compositions or pharmaceutical compositions. Provided are methods of reducing (down regulating) a target membrane-bound protein (MBP) level in a cell, methods of producing a cell having a reduced target membrane-bound protein level, or methods of treating a disease, or methods of reducing or preventing GvHD in a subject associated with the administration of one or more CAR T-cells to the subject.

Immune cells engineered to express a chimeric antigen receptor (CAR) along with a TGF-beta dominant negative receptor (TGF|3 DNR) and / or a membrane-bound IL15 protein (mbIL15) are provided which are suitable for the treatment of diseases such as cancer.

There remains a need to provide healthcare professionals treating cancer, particularly advanced or metastatic solid tumors, with more and better options. [Solution] The present invention relates to the field of binding molecules. Specifically, the present invention relates to the field of therapeutic binding molecules for the treatment of diseases involving abnormal cells such as cancer cells. In particular, the present invention relates to multispecific antibodies that bind to the extracellular portion of two or more different membrane-bound proteins and thereby modulate the biological activity expressed by the cells, and to the use of such antibodies in combination therapy.

The present invention provides the method and means for an efficient isolation of membrane-bound proteins from biological samples, e.g. in samples from raw or processed plant material, preferably defatted plant seed meal such as canola meal. The biological sample can be highly processed, e.g. by applying high temperature, pressure, or a chemical treatment and can be derived from seed matrices as well as other typical plant tissues for example seed, grain, leaf, root, or pollen. The invention comprises the provision of a novel extraction buffer (MEB) and its application in the method of the invention, wherein the buffer has a strong alkaline pH of 10 to 12.5 and comprises a soluble concentration of detergent at a level of 0.5% to 5%.

A method of expanding natural killer cells, comprising: providing a population of internal colloidal cells, wherein each internal colloidal cell comprises an internal colloidal volume and a fluid cell membrane comprising one or more membrane-bound proteins, each or collectively of which is capable of stimulating expansion of natural killer (NK) cells; and culturing a population of cells comprising NK cells capable of responding to the one or more membrane-bound proteins with the population of internal colloidal cells under conditions that allow expansion of the NK cells.

The present disclosure relates generally to envelope binding proteins and their use in methods of producing and / or purifying enveloped viruses from cell culture.